Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Revance Therapeutics, Inc.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provide written informed consent including authorization to release health information
Moderate (2) or severe (3) glabellar lines during maximum frown based on the Investigator Global Assessment Frown Wrinkle Severity (IGA-FWS) scale
Moderate (2) or severe (3) glabellar lines during maximum frown based on the Patient Frown Wrinkle Severity (PFWS) scale
Willing and able to follow all trial procedures, attend all scheduled visits, and successfully complete the trial
You may not be if
Any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type A, including peripheral motor neuropathic diseases such as amyotrophic lateral sclerosis and motor neuropathy, and neuromuscular junctional disorders such as Lambert-Eaton syndrome and myasthenia gravis
Active skin disease, infections or inflammation at the injection sites
Plan to receive botulinum toxin type A anywhere in the face through the duration of the study
History of allergy or sensitivity to any botulinum toxin preparations or to any component of the test article
Current enrollment in an investigational drug or device trial or participation in such a trial within the last 30 days prior to screening through end of trial
Clareo Health | Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
